# Efficacy and Safety of Anrikefon Injection for the Treatment of Postoperative Pain in Patients Undergoing Totally Laparoscopic Radical Distal Gastrectomy

> **NCT07330063** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 114 (estimated)

## Conditions studied

- Gastrectomy

## Interventions

- **DRUG:** Anruikefen (Intravenous Bolus)
- **DRUG:** Anruikefen (Intravenous Infusion)
- **DRUG:** Placebo Group

## Key facts

- **NCT ID:** NCT07330063
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-22
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 114 (ESTIMATED)
- **Last updated:** 2026-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07330063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07330063, "Efficacy and Safety of Anrikefon Injection for the Treatment of Postoperative Pain in Patients Undergoing Totally Laparoscopic Radical Distal Gastrectomy". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT07330063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*